In a new study led by Amra Jujic (postdoc in Martin Magnussons research group), which was published in Diabetologia in January 2020 (Jujić, A. et al. Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study.Diabetologia. 2020), it was shown that high levels of GIP are linked to a greater risk of future cardiovascular disease (CVD) and mortality as well as subclinical atherosclerosis. This was the first study in which measurements were taken across a large population to investigate the link between the levels of GIP and GLP-1 in the blood and measurements of early arteriosclerosis. But the number of diabetic participants was low in this study, so it is not known how GIP levels affect the arteriosclerosis process in a purely diabetic population.

Now Martin Magnussons and co-applicants proposed to validate how high levels of GIP associates with adverse outcomes also in exclusively diabetic subjects from the Swedish All New Diabetics in Scania cohort.Furthermore, the mechanisms behind the harmful actions mediated by GIP will be explored in two separate heart failure cohorts. In experimental studies, long-term cardiovascular effects of incretin infusion and GIP inhibition using a GIP-receptor antagonist will be examined using mouse models. Lastly in exploratory studies, Martins team will invastigate GIP and GLP-1 associations with cancer incidence and statin usage.

Read more about Martin Magnussons study at the following press release “Incretin hormone levels linked to arteriosclerosis”.